(Total Views: 307)
Posted On: 02/26/2019 3:40:30 PM
Post# of 72444
Per today's PR:
"Innovation Pharmaceuticals established the subsidiary as part of its commitment to expand development its clinical pipeline—including Brilacidin, its Host Defense Protein-mimetic drug candidate with multiple therapeutic applications, and Kevetrin, its p53-modulating anti-cancer drug candidate—for the European marketplace"
Commitment to WHOM?
Kelt
"Innovation Pharmaceuticals established the subsidiary as part of its commitment to expand development its clinical pipeline—including Brilacidin, its Host Defense Protein-mimetic drug candidate with multiple therapeutic applications, and Kevetrin, its p53-modulating anti-cancer drug candidate—for the European marketplace"
Commitment to WHOM?
Kelt
(3)
(0)Scroll down for more posts ▼
